Small and medium sized HDL particles are protectively associated with coronary calcification in a cross-sectional population-based sample

Atherosclerosis

Volumn 251, Issue , 2016, Pages 124-131

  Ditah, Chobufo ^a,b   Otvos, James ^c   Nassar, Hisham ^d   Shaham, Dorith ^d   Sinnreich, Ronit ^a   Kark, Jeremy D ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b Mankon Sub Divisional Hospital   (Cameroon)

^c LIPOSCIENCE INC   (United States)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Arabs; Coronary calcification; HDL cholesterol; HDL particles; Jews; Large HDL particles; Medium sized HDL particles; Small HDL particles

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LARGE HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDIUM HIGH DENSITY LIPOPROTEIN; SMALL HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; AGED; ARAB; ARTICLE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY CALCIFICATION; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; ISRAEL; JEW; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; POPULATION; PRIORITY JOURNAL; PROBABILITY; PROTECTION; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CALCINOSIS; CARDIAC MUSCLE; CORONARY ARTERY DISEASE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME;

AGED; BIOMARKERS; CALCINOSIS; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LIPOPROTEINS, HDL; LOGISTIC MODELS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIUM; PARTICLE SIZE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84974794160     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.06.010     Document Type: Article

References (37)

1. Kaur N., Pandey A., Negi H., Shafiq N., Reddy S., Kaur H., et al. Effect of HDL-raising drugs on cardiovascular outcomes: a systematic review and meta-regression. PLoS One 2014, 9(4):e94585.
2. Voight B.F., Peloso G.M., Orho-Melander M., Frikke-Schmidt R., Barbalic M., Jensen M.K., et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012, 380:572-580.
3. Kontush A. HDL-mediated mechanisms of protection in cardiovascular disease. Cardiovasc. Res. 2014, 103:341-349.
4. Rader D.J., Hovingh G.K. HDL and cardiovascular disease. Lancet 2014, 384:618-625.
5. Du X.-M., Kim M.-J., Hou L., Le Goff W., Chapman M.J., Van Eck M., et al. HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. Circ. Res. 2015, 116:1133-1142.
6. Camont L., Chapman M.J., Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol. Med. 2011, 17:594-603.
7. Rached F.H., Chapman M.J., Kontush A. HDL particle subpopulations: focus on biological function. BioFactors 2015, 788-795.
8. Jeyarajah E.J., Cromwell W.C., Otvos J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin. Lab. Med. 2006, 26:847-870.
9. Kulkarni K.R. Cholesterol profile measurement by vertical auto profile method. Clin. Lab. Med. 2006, 26:787-802.
10. Chapman M.J., Goldstein S., Lagrange D., Laplaud P.M. A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J. Lipid Res. 1981, 22:339-358.
11. Freeman L.A. Lipoproteins and cardiovascular disease: methods and protocols 2013, 353-367. Humana Press, Totowa, NJ. A.L. Freeman (Ed.).
12. Salonen J.T., Salonen R., Seppänen K., Rauramaa R., Tuomilehto J.H.D.L. HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation 1991, 84:129-139.
13. Lamarche B., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J., Despres J.-P. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men: prospective results from the Quebec cardiovascular study. Arterioscler. Thromb. Vasc. Biol. 1997, 17:1098-1105.
14. Kim D.S., Burt A.A., Rosenthal E.A., Ranchalis J.E., Eintracht J.F., Hatsukami T.S., et al. HDL-3 is a superior predictor of carotid artery disease in a case-control cohort of 1725 participants. J. Am. Heart Assoc. 2014, 3:e000902.
15. Yu S., Yarnell J.W.G., Sweetnam P., Bolton C.H. High density lipoprotein subfractions and the risk of coronary heart disease: 9-years follow-up in the Caerphilly Study. Atherosclerosis 2003, 166:331-338.
16. Martin S.S., Khokhar A.A., May H.T., Kulkarni K.R., Blaha M.J., Joshi P.H., et al. HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the Lipoprotein Investigators Collaborative. Eur. Heart J. 2015, 36:22-30.
17. Gebhard C., Rhainds D., Tardif J.-C. HDL and cardiovascular risk: is cholesterol in particle subclasses relevant?. Eur. Heart J. 2015, 36:10-12.
18. Mackey R.H., Greenland P., Goff D.C., Lloyd-Jones D., Sibley C.T., Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J. Am. Coll. Cardiol. 2012, 60:508-516.
19. Mora S., Glynn R.J., Ridker P.M. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation 2013, 128:1189-1197.
20. Otvos J.D., Collins D., Freedman D.S., Shalaurova I., Schaefer E.J., McNamara J.R., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-density Lipoprotein Intervention Trial. Circulation 2006, 113:1556-1563.
21. Chandra A., Neeland I.J., Das S.R., Khera A., Turer A.T., Ayers C.R., et al. Relation of black race between high density lipoprotein cholesterol content, high density lipoprotein particles and coronary events (from the Dallas Heart Study). Am. J. Cardiol. 2015, 115:890-894.
22. Rizzo M., Otvos J., Nikolic D., Montalto G., Toth P.P., Banach M. Subfractions and subpopulations of HDL: an update. Curr. Med. Chem. 2014, 2881-2891.
23. Qi Y., Fan J., Liu J., Wang W., Wang M., Sun J., et al. Cholesterol-overloaded HDL particles are independently associated with progression of carotid atherosclerosis in a cardiovascular disease-free population: a community-based cohort study. J. Am. Coll. Cardiol. 2015, 65:355-363.
24. Budoff M.J., Achenbach S., Blumenthal R.S., Carr J.J., Goldin J.G., Greenland P., et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American heart association committee on cardiovascular imaging and intervention, council on cardiovascular radiology and intervention, and committee on cardiac imaging, council on clinical cardiology. Circulation 2006, 114:1761-1791.
25. Kark J.D., Nassar H., Shaham D., Sinnreich R., Goldberger N., Aboudi V., et al. Leukocyte telomere length and coronary artery calcification in Palestinians. Atherosclerosis 2013, 229:363-368.
26. Merom D., Sinnreich R., Aboudi V., Kark J.D., Nassar H. Lifestyle physical activity among urban Palestinians and Israelis: a cross-sectional comparison in the Palestinian-Israeli Jerusalem risk factor study. BMC Public Health 2012, 12(1):90.
27. McGarrah R.W., Craig D.M., Haynes C., Dowdy Z.E., Shah S.H., Kraus W.E. High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort. Atherosclerosis 2016, 246:229-235.
28. Hecht H.S., de Siqueira M.E.M., Cham M., Yip R., Narula J., Henschke C., et al. Low- vs. standard-dose coronary artery calcium scanning. Eur. Heart J. Cardiovasc Imaging 2015, 16:358-363.
29. Joshi P.H., Patel B., Blaha M.J., Berry J.D., Blankstein R., Budoff M.J., et al. Coronary artery calcium predicts cardiovascular events in participants with a low lifetime risk of Cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2016, 246:367-373.
30. Church T.S., Levine B.D., McGuire D.K., Lamonte M.J., Fitzgerald S.J., Cheng Y.J., et al. Coronary artery calcium score, risk factors, and incident coronary heart disease events. Atherosclerosis 2007, 190:224-231.
31. Arad Y., Goodman K.J., Roth M., Newstein D., Guerci A.D. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart Study. J. Am. Coll. Cardiol. 2005, 46:158-165.
32. Hosmer David W. Stanley Lemeshow RXS. Wiley: Applied Logistic Regression 2013, Wiley, third ed.
33. Bozdogan H. Model selection and Akaike's Information Criterion (AIC): the general theory and its analytical extensions. Psychometrika 1987, 52:345-370.
34. Stata.com. lpoly - Kernel-weighted local polynomial smoothing. [cited 2015 Aug 19]. p. 1-10. Available from: . http://www.stata.com/manuals13/rlpoly.pdf.
35. Xu R.-X., Zhang Y., Ye P., Chen H., Li Y.-F., Hua Q., et al. Analysis of lipoprotein subfractions in Chinese Han patients with stable coronary artery disease. Heart Lung Circ. 2015, 1881:1-8.
36. Asztalos B.F., Collins D., Cupples L.A., Demissie S., Horvath K.V., Bloomfield H.E., et al. Value of high-density lipoprotein ( HDL ) subpopulations in predicting recurrent cardiovascular events in the veterans affairs HDL intervention trial. Arterioscler. Thromb. Vasc. Biol. 2005, 25:2185-2191.
37. Connelly M.A., Shalaurova I., Otvos J.D. High-density lipoprotein and inflammation in cardiovascular disease. Transl. Res. 2016, 1-12.